David Schwartz

Co-Founder, CEO, CSO at Cell IDx

David Schwartz is the Co-Founder, CEO, CSO at Cell IDx. David has over 30 years experience developing novel bioconjugation chemistries for both in vivo therapeutics and in vivo and in vitro diagnostics; leads the team at Cell IDx. Dr. Schwartz applied his extensive background in bio-organic chemistry, synthetic organic chemistry, and in vitro and in vivo diagnostics to develop multiplex immunofluorescence technologies.

Dr. Schwartz applied his extensive background in bio-organic chemistry, synthetic organic chemistry, and in vitro and in vivo diagnostics to develop multiplex immunofluorescence technologies. Through research funded by a NCI Phase II contract, he discovered and patented Cell IDx’s hapten-based UltraPlex multiplex immunoassay technology that allows unlimited multiplexing with high sensitivity and specificity in immunoassays. The UltraPlex technology is a first-in-class method to simultaneously detect multiple biomarkers on a single tissue specimen.

Prior to founding Cell IDx, Dr. Schwartz founded Solulink Biosciences where, as Chief Science Officer, he invented the Schiff base-based conjugation chemistry and led its commercialization. Through efforts at Dynavax, Genta, and Johnson Matthey, David applied his background in synthetic organic chemistry to medicinal chemistry and the development novel bioconjugation reagents for both therapeutics and diagnostics.

His accomplishments include being one of the inventors of the approved therapeutic Plerixafor (Mozobil; Genzyme) used for stimulation of hematopoietic stem cells for patients with lymphoma and multiple myeloma, discovery and development of HyNic for linking of Tc-99m to proteins for in vivo diagnostics, discovery and development of the aromatic hydrazine/aromatic aldehyde couple for biomolecule conjugations, methods to efficiently conjugate oligonucleotides to proteins which has led to methods and products to rapidly prepare antibody conjugates for flow cytometry and use in the proximity ligation assay, and development of a technology for multiplex imaging of tissues.

Timeline

  • Co-Founder, CEO, CSO

    Current role